{"id":"NCT01820572","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based","officialTitle":"Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03-27","primaryCompletion":"2019-10-24","completion":"2019-10-24","firstPosted":"2013-03-29","resultsPosted":"2021-01-05","lastUpdate":"2021-01-05"},"enrollment":446,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Kidney Transplantation"],"interventions":[{"type":"DRUG","name":"Belatacept","otherNames":["BMS 224818","Nulojix®"]},{"type":"DRUG","name":"Tacrolimus","otherNames":[]},{"type":"DRUG","name":"Cyclosporine","otherNames":[]}],"arms":[{"label":"Belatacept","type":"EXPERIMENTAL"},{"label":"CNI","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.","primaryOutcome":{"measure":"Percentage of Participants Who Survive With a Functional Graft at 24 Months","timeFrame":"at 24 Months","effectByArm":[{"arm":"Belatacept","deltaMin":98.2,"sd":null},{"arm":"CNI-Based Regimen","deltaMin":97.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":117,"countries":["United States","Argentina","Austria","Colombia","France","Germany","Netherlands","Norway","Sweden","Switzerland"]},"refs":{"pmids":["34706967"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":107,"n":221},"commonTop":["Diarrhoea","Nasopharyngitis","Urinary tract infection","Oedema peripheral","Cough"]}}